Novo-Azt

• Anti-HIV Agents
• Antimetabolites
• Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
• ATC:J05AF01

• AZT
• Apo-Zidovudine
• Azidothymidine
• Aztec
• Compound S
• Novo-Azt
• Retrovir
• Zidovudine EP III

Combivir (Lamivudine + Zidovudine)

Trizivir (Abacavir sulfate + Lamivudine + Zidovudine)

C₁₀H₁₃N₅O₄

http://www.rxlist.com/cgi/generic3/zidovud.htm

Novo-Azt FDA

Novo-Azt MSDS

Sugimura, Hideyuki et al, Tetrahedron Lett;.. 32, 15, 1813-1816 (1991)

267.242 g/mol

106-112 ^oC

10-50 g / L à 17 ° C

Solid

0.05

Capsule; Liquid; Sirop; Tablet

Pour le traitement de l'immunodéficience humaine (VIH).

La zidovudine est un inhibiteur nucléosidique de la transcriptase inverse (INTI) avec une activité contre les virus d'immunodéficience humaine de type 1 (VIH-1). La zidovudine est phosphorylée en métabolites actifs qui rivalisent pour incorporation dans l'ADN viral. Ils inhibent l'enzyme transcriptase inverse du VIH compétitifs et agir comme un terminateur de chaîne de synthèse d'ADN. L'absence d'un groupe 3'-OH dans l'analogue nucléosidique incorporé empêche la formation de l'extrémité 5 'à 3' liaison phosphodiester essentiel pour l'élongation de la chaîne d'ADN, et donc la croissance d'ADN viral est terminée.

Absorption rapide et presque complète de l'appareil gastro-intestinal après administration orale, toutefois, à cause de premier passage hépatique, la biodisponibilité systémique de gélules de zidovudine et la solution est d'environ 65% (fourchette de 52 à 75%). La biodisponibilité des nouveau-nés jusqu'à 14 jours d'âge est d'environ 89%, et elle diminue à environ 61% et 65% des nouveau-nés de plus de 14 jours d'âge et les enfants 3 mois à 12 ans, respectivement. Administration avec un repas riche en graisses peut diminuer le taux et l'étendue de l'absorption.

Les symptômes de surdose comprennent la fatigue, des céphalées, des nausées et des vomissements. DL50 est 3084 mg / kg (par voie orale chez la souris).

RETROVIR is not a cure for HIV infection, and patients may continue to acquire illnesses associated with HIV infection, including opportunistic infections. Therefore, patients should be advised to seek medical care for any significant change in their health status.

The safety and efficacy of RETROVIR in women, intravenous drug users, and racial minorities is not significantly different than that observed in white males.

Patients should be informed that the major toxicities of RETROVIR are neutropenia and/or anemia. The frequency and severity of these toxicities are greater in patients with more advanced disease and in those who initiate therapy later in the course of their infection. They should be told that if toxicity develops, they may require transfusions or drug discontinuation. They should be told of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced symptomatic HIV disease. They should be cautioned about the use of other medications, including ganciclovir and interferon-alpha, that may exacerbate the toxicity of RETROVIR. Patients should be informed that other adverse effects of RETROVIR include nausea and vomiting. Patients should also be encouraged to contact their physician if they experience muscle weakness, shortness of breath, symptoms of hepatitis or pancreatitis, or any other unexpected adverse events while being treated with RETROVIR.

RETROVIR Tablets, Capsules, and Syrup are for oral ingestion only. Patients should be told of the importance of taking RETROVIR exactly as prescribed. They should be told not to share medication and not to exceed the recommended dose. Patients should be told that the long-term effects of RETROVIR are unknown at this time.

Pregnant women considering the use of RETROVIR during pregnancy for prevention of HIV-transmission to their infants should be advised that transmission may still occur in some cases despite therapy. The long-term consequences of in utero and infant exposure to RETROVIR are unknown, including the possible risk of cancer.

HIV-infected pregnant women should be advised not to breastfeed to avoid postnatal transmission of HIV to a child who may not yet be infected.

Patients should be advised that therapy with RETROVIR has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

Virus d'immunodéficience humaine